Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum

Neurobiology of Aging

Volumn 46, Issue , 2016, Pages 32-42

  Knopman, David S ^a   Jack, Clifford R ^a   Lundt, Emily S ^a   Weigand, Stephen D ^a   Vemuri, Prashanthi ^a   Lowe, Val J ^a   Kantarci, Kejal ^a   Gunter, Jeffrey L ^a   Senjem, Matthew L ^a   Mielke, Michelle M ^a   Machulda, Mary M ^a   Roberts, Rosebud O ^a   Boeve, Bradley F ^a   Jones, David T ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; FDG PET imaging; Longitudinal study; MR imaging; PIB PET imaging

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CEREBELLUM VERMIS; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; LINEAR REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VERY ELDERLY; AGING; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; HIPPOCAMPUS; PARIETAL LOBE; PATHOLOGY; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; TEMPORAL LOBE;

EID: 84978208857     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.06.003     Document Type: Article

References (64)

1. Albert, M., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H., Fox, N.C., Gamst, A., Holtzman, D., Jagust, W.J., Petersen, R.C., Snyder, P.J., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Demen. J. Alzheimer's Assoc. 7 (2011), 270–279.
2. Araque Caballero, M.A., Brendel, M., Delker, A., Ren, J., Rominger, A., Bartenstein, P., Dichgans, M., Weiner, M.W., Ewers, M., Mapping 3-year changes in gray matter and metabolism in Abeta-positive nondemented subjects. Neurobiol. Aging 36 (2015), 2913–2924.
3. Ashburner, J., Computational anatomy with the SPM software. Magn. Reson. Imaging 27 (2009), 1163–1174.
4. Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., Del Tredici, K., Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112 (2006), 389–404.
5. Braak, H., Braak, E., Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82 (1991), 239–259.
6. Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N.J., Holtzman, D.M., Fagan, A.M., Morris, J.C., Benzinger, T.L., Ances, B.M., Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease. Sci. Transl. Med., 8, 2016, 338ra366.
7. Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W.M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C., Wall, A.E., Carter, S.F., Scholl, M., Choo, I.H., Grimmer, T., Redolfi, A., Nordberg, A., Scheltens, P., Drzezga, A., Frisoni, G.B., Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84 (2015), 508–515.
8. Delacourte, A., David, J.P., Sergeant, N., Buee, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., Pasquier, F., Lebert, F., Petit, H., Di Menza, C., The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 52 (1999), 1158–1165.
9. Dickerson, B.C., Stoub, T.R., Shah, R.C., Sperling, R.A., Killiany, R.J., Albert, M.S., Hyman, B.T., Blacker, D., Detoledo-Morrell, L., Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 76 (2011), 1395–1402.
10. Dore, V., Villemagne, V.L., Bourgeat, P., Fripp, J., Acosta, O., Chetelat, G., Zhou, L., Martins, R., Ellis, K.A., Masters, C.L., Ames, D., Salvado, O., Rowe, C.C., Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol. 70 (2013), 903–911.
11. Duyckaerts, C., Bennecib, M., Grignon, Y., Uchihara, T., He, Y., Piette, F., Hauw, J.J., Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol. Aging 18 (1997), 267–273.
12. Ewers, M., Insel, P., Jagust, W.J., Shaw, L., Trojanowski, J.Q., Aisen, P., Petersen, R.C., Schuff, N., Weiner, M.W., CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb. Cortex 22 (2012), 1993–2004.
13. Gelman, A., Hill, J., Data Analysis Using Regression and Multilevel/Hierarchical Models. 2007, Cambridge University Press, New York, NY.
14. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., Parisi, J.E., Hyman, B.T., Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41 (1997), 17–24.
15. Jack, C.R. Jr., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L., Senjem, M.L., Ivnik, R.J., Roberts, R.O., Rocca, W.A., Boeve, B.F., Petersen, R.C., An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71 (2012), 765–775.
16. Jack, C.R. Jr., Lowe, V.J., Senjem, M.L., Weigand, S.D., Kemp, B.J., Shiung, M.M., Knopman, D.S., Boeve, B.F., Klunk, W.E., Mathis, C.A., Petersen, R.C., 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131 (2008), 665–680.
17. Jack, C.R. Jr., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., Shiung, M.M., Gunter, J.L., Boeve, B.F., Kemp, B.J., Weiner, M., Petersen, R.C., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132 (2009), 1355–1365.
18. Jack, C.R. Jr., Wiste, H.J., Knopman, D.S., Vemuri, P., Mielke, M.M., Weigand, S.D., Senjem, M.L., Gunter, J.L., Lowe, V., Gregg, B.E., Pankratz, V.S., Petersen, R.C., Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 82 (2014), 1605–1612.
19. Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., Pankratz, V.S., Senjem, M.L., Gunter, J.L., Mielke, M.M., Lowe, V.J., Boeve, B.F., Petersen, R.C., Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
20. Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Knopman, D.S., Vemuri, P., Mielke, M.M., Lowe, V., Senjem, M.L., Gunter, J.L., Machulda, M.M., Gregg, B.E., Pankratz, V.S., Rocca, W.A., Petersen, R.C., Age, sex, and APOE e4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol. 72 (2015), 511–519.
21. Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Rocca, W.A., Knopman, D.S., Mielke, M.M., Lowe, V.J., Senjem, M.L., Gunter, J.L., Preboske, G.M., Pankratz, V.S., Vemuri, P., Petersen, R.C., Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 13 (2014), 997–1005.
22. Jack, C.R., Petersen, R.C., Xu, Y.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Waring, S.C., Tangalos, E.G., Kokmen, E., Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52 (1999), 1397–1403.
23. Jack, C.R.J., Wiste, H.J., Weigand, S.D., Knopman, D.S., Mielke, M.M., Vemuri, P., Lowe, V., Senjem, M.L., Gunter, J.L., Reyes, D., Machulda, M.M., Roberts, R., Petersen, R.C., Different definitions of neurodegeneration produce similar frequencies of amyloid and neurodegeneration biomarker groups by age among cognitively non-impaired individuals. Brain 138 (2015), 3747–3759.
24. Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., Marshall, G., Albers, M., Mauro, S., Pepin, L., Alverio, J., Judge, K., Philiossaint, M., Shoup, T., Yokell, D., Dickerson, B., Gomez-Isla, T., Hyman, B., Vasdev, N., Sperling, R., Tau PET imaging in aging and early Alzheimer's disease. Ann. Neurol. 79 (2016), 110–119.
25. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausen, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Langstrom, B., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004), 306–319.
26. Knol, M.J., Pestman, W.R., Grobbee, D.E., The (mis)use of overlap of confidence intervals to assess effect modification. Eur. J. Epidemiol. 26 (2011), 253–254.
27. Knopman, D.S., Jack, C.R. Jr., Lundt, E.S., Wiste, H.J., Weigand, S.D., Vemuri, P., Lowe, V.J., Kantarci, K., Gunter, J.L., Senjem, M.L., Mielke, M.M., Machulda, M.M., Roberts, R.O., Boeve, B.F., Jones, D.T., Petersen, R.C., Role of beta-amyloidosis and neurodegeneration in subsequent imaging changes in mild cognitive impairment. JAMA Neurol. 72 (2015), 1475–1483.
28. Knopman, D.S., Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L., Senjem, M., Ivnik, R.J., Roberts, R.O., Boeve, B.F., Petersen, R.C., Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78 (2012), 1576–1582.
29. Knopman, D.S., Jack, C.R.J., Wiste, H.J., Weigand, S.D., Vemuri, P., Lowe, V.J., Kantarci, K., Gunter, J.L., Senjem, M.L., Mielke, M.M., Roberts, R.O., Boeve, B.F., Petersen, R.C., Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly with β-amyloidosis. JAMA Neurol. 70 (2013), 1030–1038.
30. La Joie, R., Perrotin, A., Barre, L., Hommet, C., Mezenge, F., Ibazizene, M., Camus, V., Abbas, A., Landeau, B., Guilloteau, D., de La Sayette, V., Eustache, F., Desgranges, B., Chetelat, G., Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J. Neurosci. 32 (2012), 16265–16273.
31. Landau, S.M., Harvey, D., Madison, C.M., Koeppe, R.A., Reiman, E.M., Foster, N.L., Weiner, M.W., Jagust, W.J., Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 32 (2011), 1207–1218.
32. Lemaitre, H., Crivello, F., Dufouil, C., Grassiot, B., Tzourio, C., Alperovitch, A., Mazoyer, B., No epsilon4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage 24 (2005), 1205–1213.
33. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R.J., Kawas, C.H., Klunk, W.E., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimer's Demen. J. Alzheimer's Assoc. 7 (2011), 263–269.
34. Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., Johnson, K.A., Sperling, R.A., Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71 (2014), 1379–1385.
35. Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., Mintun, M.A., APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67 (2010), 122–131.
36. Murray, M.E., Lowe, V.J., Graff-Radford, N.R., Liesinger, A.M., Cannon, A., Przybelski, S.A., Rawal, B., Parisi, J.E., Petersen, R.C., Kantarci, K., Ross, O.A., Duara, R., Knopman, D.S., Jack, C.R. Jr., Dickson, D.W., Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 138 (2015), 1370–1381.
37. Nosheny, R.L., Insel, P.S., Truran, D., Schuff, N., Jack, C.R. Jr., Aisen, P.S., Shaw, L.M., Trojanowski, J.Q., Weiner, M.W., Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol. Aging 36 (2015), 273–282.
38. Oh, H., Madison, C., Villeneuve, S., Markley, C., Jagust, W.J., Association of gray matter atrophy with age, beta-amyloid, and cognition in aging. Cereb. Cortex 24 (2014), 1609–1618.
39. Petersen, R.C., Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256 (2004), 183–194.
40. Petersen, R.C., Aisen, P., Boeve, B.F., Geda, Y.E., Ivnik, R.J., Knopman, D.S., Mielke, M.M., Pankratz, V.S., Roberts, R., Rocca, W.A., Weigand, S., Weiner, M., Wiste, H.J., Jack, C.R., Mild cognitive impairment due to Alzheimer's disease: criteria in the community. Ann. Neurol. 74 (2013), 199–208.
41. Petersen, R.C., Roberts, R.O., Knopman, D.S., Geda, Y.E., Cha, R.C., Pankratz, V.S., Boeve, B.F., Tangalos, E.G., Ivnik, R.J., Rocca, W.A., Prevalence of mild cognitive impairment is higher in men than in women. The Mayo Clinic Study of Aging. Neurology 75 (2010), 889–897.
42. Pooler, A.M., Polydoro, M., Maury, E.A., Nicholls, S.B., Reddy, S.M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., Beier, D.R., Carlson, G.A., Spires-Jones, T.L., Hyman, B.T., Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta Neuropathol. Commun., 3, 2015, 14.
43. Prestia, A., Caroli, A., van der Flier, W.M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C.E., Wall, A.E., Carter, S.F., Scholl, M., Choo, I.H., Nordberg, A., Scheltens, P., Frisoni, G.B., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80 (2013), 1048–1056.
44. Roberts, R.O., Geda, Y.E., Knopman, D., Cha, R., Pankratz, V.S., Boeve, B., Ivnik, R., Tangalos, E., Petersen, R.C., Rocca, W.A., The Mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30 (2008), 58–69.
45. Roberts, R.O., Geda, Y.E., Knopman, D.S., Cha, R.H., Pankratz, V.S., Boeve, B.F., Tangalos, E.G., Ivnik, R.J., Rocca, W.A., Petersen, R.C., The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology 78 (2012), 342–351.
46. Roberts, R.O., Knopman, D.S., Mielke, M.M., Cha, R.H., Pankratz, V.S., Christianson, T.J., Geda, Y.E., Boeve, B.F., Ivnik, R.J., Tangalos, E.G., Rocca, W.A., Petersen, R.C., Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology 82 (2014), 317–325.
47. Roe, C.M., Fagan, A.M., Grant, E.A., Hassenstab, J., Moulder, K.L., Maue Dreyfus, D., Sutphen, C.L., Benzinger, T.L., Mintun, M.A., Holtzman, D.M., Morris, J.C., Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80 (2013), 1784–1791.
48. Sabuncu, M.R., Desikan, R.S., Sepulcre, J., Yeo, B.T., Liu, H., Schmansky, N.J., Reuter, M., Weiner, M.W., Buckner, R.L., Sperling, R.A., Fischl, B., The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch. Neurol. 68 (2011), 1040–1048.
49. Savva, G.M., Wharton, S.B., Ince, P.G., Forster, G., Matthews, F.E., Brayne, C., Age, neuropathology, and dementia. N. Engl. J. Med. 360 (2009), 2302–2309.
50. Scholl, M., Lockhart, S.N., Schonhaut, D.R., O'Neil, J.P., Janabi, M., Ossenkoppele, R., Baker, S.L., Vogel, J.W., Faria, J., Schwimmer, H.D., Rabinovici, G.D., Jagust, W.J., PET imaging of tau deposition in the aging human brain. Neuron 89 (2016), 971–982.
51. Schuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L.M., Trojanowski, J.Q., Thompson, P.M., Jack, C.R. Jr., Weiner, M.W., MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132 (2009), 1067–1077.
52. Schwarz, A.J., Yu, P., Miller, B.B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A.D., Devous, M.D. Sr., Mintun, M.S., Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139 (2016), 1539–1550.
53. Thal, D.R., Rub, U., Schultz, C., Sassin, I., Ghebremedhin, E., Del Tredici, K., Braak, E., Braak, H., Sequence of Abeta-protein deposition in the human medial temporal lobe. J. Neuropathol. Exp. Neurol. 59 (2000), 733–748.
54. Toledo, J.B., Weiner, M.W., Wolk, D.A., Da, X., Chen, K., Arnold, S.E., Jagust, W., Jack, C., Reiman, E.M., Davatzikos, C., Shaw, L.M., Trojanowski, J.Q., Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol. Commun., 2, 2014, 26.
55. Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., Joliot, M., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15 (2002), 273–289.
56. van Harten, A.C., Smits, L.L., Teunissen, C.E., Visser, P.J., Koene, T., Blankenstein, M.A., Scheltens, P., van der Flier, W.M., Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81 (2013), 1409–1416.
57. van Rossum, I.A., Vos, S.J., Burns, L., Knol, D.L., Scheltens, P., Soininen, H., Wahlund, L.O., Hampel, H., Tsolaki, M., Minthon, L., L'Italien, G., van der Flier, W.M., Teunissen, C.E., Blennow, K., Barkhof, F., Rueckert, D., Wolz, R., Verhey, F., Visser, P.J., Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79 (2012), 1809–1816.
58. Vemuri, P., Senjem, M.L., Gunter, J.L., Lundt, E.S., Tosakulwong, N., Weigand, S.D., Borowski, B.J., Bernstein, M.A., Zuk, S.M., Lowe, V.J., Knopman, D.S., Petersen, R.C., Fox, N.C., Thompson, P.M., Weiner, M.W., Jack, C.R. Jr., Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. Neuroimage 113 (2015), 61–69.
59. Vemuri, P., Wiste, H.J., Weigand, S.D., Knopman, D.S., Shaw, L.M., Trojanowski, J.Q., Aisen, P.S., Weiner, M., Petersen, R.C., Jack, C.R. Jr., Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann. Neurol. 67 (2010), 308–316.
60. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, C.C., Masters, C.L., Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12 (2013), 357–367.
61. Vos, S.J., Verhey, F., Frolich, L., Kornhuber, J., Wiltfang, J., Maier, W., Peters, O., Ruther, E., Nobili, F., Morbelli, S., Frisoni, G.B., Drzezga, A., Didic, M., van Berckel, B.N., Simmons, A., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Muscio, C., Herukka, S.K., Salmon, E., Bastin, C., Wallin, A., Nordlund, A., de Mendonca, A., Silva, D., Santana, I., Lemos, R., Engelborghs, S., Van der Mussele, S., Freund-Levi, Y., Wallin, A.K., Hampel, H., van der Flier, W., Scheltens, P., Visser, P.J., Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138 (2015), 1327–1338.
62. Vos, S.J., Xiong, C., Visser, P.J., Jasielec, M.S., Hassenstab, J., Grant, E.A., Cairns, N.J., Morris, J.C., Holtzman, D.M., Fagan, A.M., Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12 (2013), 957–965.
63. Whitwell, J.L., Josephs, K.A., Murray, M.E., Kantarci, K., Przybelski, S.A., Weigand, S.D., Vemuri, P., Senjem, M.L., Parisi, J.E., Knopman, D.S., Boeve, B.F., Petersen, R.C., Dickson, D.W., Jack, C.R. Jr., MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71 (2008), 743–749.
64. Wirth, M., Oh, H., Mormino, E.C., Markley, C., Landau, S.M., Jagust, W.J., The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement. 9 (2013), 687–698.e1.